Kolon Life Science Appoints Kim Seon-jin as New CEO

Kolon Life Science announced on the 28th that it held a general shareholders' meeting and a board meeting, appointing Kim Seon-jin as the new CEO.

New CEO Kim holds a Ph.D. in Urology from Seoul National University College of Medicine and served as a professor at the University of Texas MD Anderson Cancer Center, a world-renowned cancer center in the United States, for 19 years. He is recognized as a global authority in clinical translational research and orthotopic model development in clinical fields.

The company stated that based on Kim's diverse experience and expertise in the bio industry, it plans to accelerate clinical trials and commercialization of new drug pipelines such as the neuropathic pain treatment 'KLS-2031.' Since 2020, Kim has also joined Kolon TissueGene, leading the resumption of the U.S. Phase 3 clinical trial for the osteoarthritis cell and gene therapy 'TG-C (Invossa).' Kolon Life Science is promoting the development and commercialization of TG-C in the Asian region as one of its main businesses.

CEO Kim expressed his ambition, saying, “It is important to have the aspiration to work with an innovative and excellent research attitude and become a 'WINNER' who creates a new wave and wins.” He added, “As the new leader of Kolon Life Science, I will not hesitate to take on the development of differentiated new drugs and therapies, including in the chemical field, with an innovative perspective, and will firmly maintain our position as a leader in the bio industry through superior product competitiveness.”